BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37698683)

  • 21. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
    Shu J; Jiang J; Zhao G
    Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
    Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
    Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Hub Genes in the Immune Microenvironment of Lung Adenocarcinoma by Estimation.
    Liu S; Tian W; Li B
    Comb Chem High Throughput Screen; 2022; 25(1):77-89. PubMed ID: 33308118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel anoikis-related prognostic signature associated with prognosis and immune infiltration landscape in lung adenocarcinoma.
    Liu Y; Hu S; Teng M; Qing Y; Dong X; Chen L; Ai K
    J Gene Med; 2024 Feb; 26(1):e3610. PubMed ID: 37985130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Circulating Tumour Cell-Related Risk Model Indicates Prognosis and Immune Infiltration in Lung Adenocarcinoma.
    Liang L; Liu Y; Jiang S; Huang J; He H; Shen L; Cong L; Jiang Y
    J Immunol Res; 2022; 2022():6521290. PubMed ID: 35677538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased HLF Expression Predicts Poor Survival in Lung Adenocarcinoma.
    Wang Z; Li X; Chen H; Han L; Ji X; Wang Q; Wei L; Miao Y; Wang J; Mao J; Zhang Z
    Med Sci Monit; 2021 May; 27():e929333. PubMed ID: 33979320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of
    Bian T; Zhang W; Wang F; Chu X; Pan X; Ruan J; Yu S; Liu L; Sun H; Qiu H; Li Y; Tang J; Zhao X; Zhang H
    Comb Chem High Throughput Screen; 2023; 26(14):2452-2468. PubMed ID: 37038295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High Expression of
    Deng H; Huang Y; Wang L; Chen M
    Biomed Res Int; 2020; 2020():2071593. PubMed ID: 33134373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of Fatty Acid Metabolism in Lung Adenocarcinoma to Guide Clinical Treatment.
    Huang D; Tang E; Zhang T; Xu G
    Front Immunol; 2022; 13():916284. PubMed ID: 35860256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive analysis of the autophagy-dependent ferroptosis-related gene FANCD2 in lung adenocarcinoma.
    Miao H; Ren Q; Li H; Zeng M; Chen D; Xu C; Chen Y; Wen Z
    BMC Cancer; 2022 Mar; 22(1):225. PubMed ID: 35236309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
    Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
    BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The screening of immune-related biomarkers for prognosis of lung adenocarcinoma.
    Liu Z; Sun D; Zhu Q; Liu X
    Bioengineered; 2021 Dec; 12(1):1273-1285. PubMed ID: 33870858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An integrated analysis of prognostic and immune infiltrates for hub genes as potential survival indicators in patients with lung adenocarcinoma.
    Xu Z; Wang S; Ren Z; Gao X; Xu L; Zhang S; Ren B
    World J Surg Oncol; 2022 Mar; 20(1):99. PubMed ID: 35354488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction and validation of a mitochondria-associated genes prognostic signature and immune microenvironment characteristic of sepsis.
    Shu Q; Du Y; She H; Mo J; Zhu Z; Zhong L; He F; Fan J; Zhu J
    Int Immunopharmacol; 2024 Jan; 126():111275. PubMed ID: 37995567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High Expression of
    Chen Y; Zhou M; Gu X; Wang L; Wang C
    Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of prognostic genes in the tumor microenvironment of lung adenocarcinoma.
    Xu ZY; Zhao M; Chen W; Li K; Qin F; Xiang WW; Sun Y; Wei J; Yuan LQ; Li SK; Lin SH
    PeerJ; 2020; 8():e9530. PubMed ID: 32775050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genome‑wide investigation of the clinical significance and prospective molecular mechanisms of kinesin family member genes in patients with lung adenocarcinoma.
    Zhang L; Zhu G; Wang X; Liao X; Huang R; Huang C; Huang P; Zhang J; Wang P
    Oncol Rep; 2019 Sep; 42(3):1017-1034. PubMed ID: 31322267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.